Founder of "The Contrarian", a premium research service, featuring the "Bet The Farm" Portfolio. Actively investing since 1995, I have soared like an eagle, and been unmercifully humbled by the markets. Achieved positive returns in 2008, and turned an account with $60,310 on 1/1/2009 into an account with $3,177,937 on 11/30/2009. My best years have been 1995-2003, 2008-2012, and 2016-????. My worst years were 2013-2015. I believe inflation is coming, and we are at an inflection point in the markets.
Twenty year career as an investment analyst, investor, portfolio manager, consultant, and writer. Founder of Koldus Contrarian Investments, Ltd, which was incorporated in the spring of 2009. Dyed in the wool contrarian investor, who has learned, the hard way, that a good contrarian is only contrarian 20% of the time, but being right at key inflection points is the key to meaningful wealth creation in the markets. I believe we are near a meaningful inflection point, perhaps the biggest one yet, for the third time in the past 15 years.
Historically, I have had huge wins and impressive losses based on a concentrated, contrarian strategy. Trying to keep the good while filtering out the bad.
Seeking to run an all weather portfolio with minimal volatility and index overlays to capture my strategic and tactical recommendations along with a concentrated best ideas portfolio, which is my bread and butter, but the volatility only makes it suitable for a small piece of an investor's overall portfolio. The following are a couple of my favorite investment quotes.
"Life and investing are long ballgames." Julian Robertson
"A diamond is a chunk of coal that is made good under pressure."
"Knowledge is limited. Imagination encircles the world." Albert Einstein
I’ve been on top of the world, and the world has been on top of me. I have learned to enjoy the perspective from each view, and use opportunities to persistently acquire knowledge, and enjoy the company of those around me, especially loved ones, family, and friends.
At heart, I am a market historian with an unrivaled passion for the capital markets. I have had a long history and specialization with concentrated positions and options trading. Made money in 2008 with a net long portfolio, deploying capital in some of the market's darkest hours into long positions including purchases of American Express, Atlas Energy, Crosstex, First Industrial Real Estate, General Growth Properties, Genworth, Macquarie Infrastructure, Ruth Chris Steakhouse, and Vornado near their lows. Shorting, hedging, and option strategies also helped me in 2007 and 2009, and these are skills that I have developed ever since I started trading heavily in 1996.I enjoy reading, accumulating knowledge, and putting this knowledge to work in the active capital markets, learning lessons along the way.To this day, I continue to learn, and some of these learning lessons have been excruciatingly difficult ones, especially over the past several years, as I made mistakes allocating capital, including a sizable portion of my own capital (I always invest alongside my clients), to commodity related stocks. While all commodity related stocks have struggled since April of 2011, coal companies, which attracted me due to their extremely cheap valuations, and out-of-favor status (I am a strong believer in behavioral finance alongside fundamentals and technicals) have been the worst investing mistake of my career. The focus on the commodity arena has been the biggest mistake of my investment career thus far, yet in its aftermath, I see tremendous opportunity, even larger in scope than the fortuitous 2008/2009 environment.The capital that I accumulated and the confidence gained in navigating the treacherous investment waters of 2008 gave me the confidence to launch my own investment firm in the spring of 2009, right before the ultimate lows in the stock market. At the time I was working as a senior analyst at one of the largest RIA's in the country, and I felt strongly that the market environment was the best time since 1974/1975 to start an investment firm.
Prior to starting my firm, I was a senior analyst for three different firms over approximately 10 years (Charles Schwab, Redwood, Oxford), moving up in responsibility and scope at each stop along my journey. Since I was a paperboy, I have always had an interest in the investment markets. I love researching and finding opportunities. I am a Chartered Financial Analyst, CFA, as well as a Chartered Alternative Investment Analyst, CAIA. After starting in the teaching program at Ball State University, I switched to a career in finance when I turned a small student loan into a substantial amount of capital. I graduated summa cum laude with a degree in finance from Ball State.
Full disclosure, I am not currently a registered investment advisor, though I did serve in this capacity from 2009-2014, while owning Koldus Contrarian Investments, Ltd. Additionally, I held various securities licenses from 2000-2014, without a single complaint filed, and I continue to hold industry designations. At the end of 2014, I voluntarily let my state registration expire, as I transitioned the business to a different structure. Prior to this, I had passed, and held, various securities exams and licenses, including the Series 7, Series 63, and Series 65 exams, in addition to others, alongside my CFA and CAIA designations. Unfortunately, I did not file the proper paperwork to withdraw my state registration, and I did not disclose a personal arrangement, and subsequent civil case, between myself and a former close personal friend and client, that was initiated in 2011. I was unaware that I was required to disclose these items, and my securities attorney, at the time, did not advise me to do so. Previously, I had managed a portfolio for this gentleman, and we had taken an investment of approximately $7 million in 2009, and grown it to over $25 million at the beginning of 2012. After a difficult year of performance, an employee of the firm I owned, and friend, resigned in early 2013, and took the aforementioned client to a competing firm. As a result of not filing the proper paperwork, I agreed to a settlement, with a potential $2500 fine in the future, depending on if I choose to reapply to be a non-exempt advisor.
Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
Professional investor and overall good guy. Disclaimer: By reading Mako Research reports, you agree to use the information at your own risk. In no event should Mako Research or any affiliated party be liable for any direct or indirect trading losses caused by information contained in the research reports. Research reports are not investment advice or a recommendation or solicitation to transact any securities. Mako Research is not a registered investment advisor. You agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that Mako Research stands to profit in the event the issuer’s stock declines. Research reports may contain opinions, which are based upon generally available public information, field research, inferences and deductions through due diligence and analytical processes. All information is believed to be accurate and reliable, and has been obtained from public sources. Mako Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information. All expressions of opinion are subject to change without notice, and Mako Research is not obligated to update or supplement any reports or any of the information, analysis and opinion contained in them. You should assume that Mako Research has and/or will submit findings with the Securities Exchange Commission, and other entities that may find the information useful.
All opinions and research published and shared here are for the public good based on our best-efforts to help you in your own due diligence. All research presented and opinions are based on available public information. All investors are recommended to do their own work and not rely on internet message boards or blogs.
Investor/trader focused on discovering under the radar stocks and alpha generating ideas for my readers. Additionally, I try to give a differentiated take on names readers might already be familiar with. My specialty is looking specifically for opportunities to achieve high % gains within a year's timeframe (ROTY- Runners of the Year). Last but not least, I highlight risk management and entry/exit strategies quite a bit, as I believe they represent areas that are often neglected but materially important for readers to understand and apply.
TipRanks Top 150 First Half 2017 (Top 100 First Quarter)
My biggest successes have been in the biotech arena (over $300k personal portfolio profits), while my biggest losses have been due to overconfidence and a failure to adequately heed the bear thesis on my picks.
As always, all posts are my personal opinion. None of my material should be considered as investment advice, as readers must make their own decisions based on their own financial situations or are encouraged to utilize an investment professional (CFP, etc). Trading and investing in stocks can be very risky, and investors can lose up to 100% of principal in the event of adverse circumstances. By reading my material readers are agreeing to the above and assuming all responsibility for their own investment decisions.
FAQ (Frequently Asked Questions)
1: Why don't you have positions in each of the ROTY model account ideas?
It's a great question, one I've been getting recently and good for those who have asked it. Long story short, I've cashed out the majority of my portfolio, including gains from previous years, to buy a condo here in Peru, the kind I've always wanted but never thought I'd be able to afford. I'm very thankful for where trading and investing has taken me up to this point. I also used the funds with my wife to start her retail clothing chain, one which has a unique premise and wide moat. After we finish furnishing the place as well as get her business into a dominant self-sustaining position, I plan to turn future cashflow toward ROTY investing. The scalable ROTY model account is a transparent manner for me to show readers in real-time how I would be going about my trades in hopes that they find it useful, regardless of their account size.
2: What should I do if a binary catalyst or key event is coming for a stock that I own?
Again, I don't give advice, but what I would do personally depends on the situation. In general we try to purchase stocks months or even over a year out before such an event happens, so that we can "play the runup". If for example a stock rises 50% prior to the event, an investor can take full profits (sell the position) before the event if he or she has low risk tolerance (ie. doesn't want to lose money). If the investor has higher risk tolerance (I'm in this category generally), he or she can take partial profits (ie. sell 25% to 75% of shares) and hold the rest. If the trial data is positive or treatment is approved by the FDA or earnings are outstanding, then the investor will enjoy that big gain and bank the money. However, if the event has a disappointing result, at least you've already locked in gains and lose less. Just my two cents and how I typically operate.
3. What is your motivation in writing?
Put simply, ¨teach a man to fish.¨ When I bought my first handful of stocks I had no one to give me some guidance, thus having to learn through trial and error, quite a few highs and lots of emotional lows. My goal is to shorten the learning curve for readers, helping them learn from my mistakes and experience. Also, I simply enjoy the writing process a lot, reporting on exciting stocks with catalysts and discussing due diligence, strategy and risk management.
We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
We do not discuss unpublished reports, or provide any advanced warning of future reports to others.
We are not advisors. Please DM or e-mail email@example.com for idea generation, questions, etc.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution. My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector. I am a contributing writer at CNA Finance and cover emerging opportunities as well as breaking news events.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I'm a private, full time trader interested in both long and short ideas. My training and background are in engineering including a decade of consulting engineering practice. I've since switched over to investing/trading which I've done full time for 15+ years and to which I bring a contrarian style. I've also recently become interested in writing and have published editorials at Forbes, PJM, and a few legacy newspapers.
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
I run The Broken Leg (www.brokenleginvesting.com), a complete do-it-for-me investing solution focusing on high performance deep value strategies. We help investors who lack either the skill or the time needed to invest run a high performance deep value portfolio based on proven strategies used by folks like Walter Schloss, Ben Graham, and young Warren Buffett.
I'm also author of Net Net Hunter (www.netnethunter.com), a site dedicated to teaching new deep value investors how to run a net net stock strategy and dramatically speed up the time it takes for investors to identify and select high quality international net net stocks. We identify net nets from 28 different countries and have a thriving community of international investors.
Elephant Analytics has 15 years of analytical experience and unique skills in numerical analysis and practical mathematics. He achieved a top 50 score on the Bloomberg Aptitude Test measuring financial aptitude (out of nearly 200,000 test takers). He has also achieved a score (153) in the 99.98th percentile on the WAIS-III IQ test and has led multiple teams that have won awards during business and strategy competitions involving numerical analysis. In one such competition, he captained his team to become North American champions, finishing ahead of top Ivy League MBA teams, and represented North America in the Paris finals.
Elephant Analytics also co-founded a company that was selected as one of 25 companies to participate in an start-up incubator program that eventually spawned several companies with $100+ million valuations. He also developed the economic model for a mobile app that has generated over $1 million in revenue with minimal advertising.
Legal Disclaimer: Elephant Analytics' reports, premium research service and other writings are personal opinions only and should not be considered as investment advice. Only registered investment advisors can provide personalized investment advice. While Elephant Analytics attempts to provide reports that include accurate facts, investors should do their own diligence and fact checking prior to making their own decisions.
I am a Research Analyst and Economic Contributor for the currency exchange company, World First. Hailing from the harsh winters of Amish-dominated Wisconsin, I began investing in 2008 while still a student at the age of 18. My starting portfolio was made up of Visa (V) at its IPO, Realty Income (O), and Google (Googl).
My writing tends to inform with humor, and is dominated by how macro-economic trends affect companies and constitute headwinds and tailwinds for future returns.
For continuing macro musings (particularly in reference to the currency markets) see my company blog at http://www.worldfirst.com/us/blog/
A graduate of both Harvard Law School and Harvard Business School, George Putnam, III first became involved with distressed securities as a lawyer in the late 1970s. Seeing the inefficient niche that bankruptcies and turnarounds were presented and researched, he founded New Generation Research, Inc. and began publishing The Turnaround Letter in 1986. Since then he has frequently been quoted in Barron's, The Wall Street Journal, New York Times, USA Today and other financial publications. In 1990, he was named investment advisor of the year by USA Today. In addition to his responsibilities at New Generation Research, Inc., Mr. Putnam also serves as a trustee for The Putnam Companies, a mutual fund group with over $100 billion in assets.
Bill Gunderson @billgunderson is the CEO and Chief Market Strategist of Gunderson Capital Managment in San Diego, CA.
He is also a professional money manager, former research analyst, author of Best Stocks Now, and developer of the Best Stocks Now smartphone app.
He offers four free weeks to his weekly Best Stocks Now to Seeking Alpha readers at gundersoncapital.com
He also hosts a daily stock market radio show that is syndicated nationwide on the Salem Broadcast Network.
Bill has appeared on the Fox Business Channel and on Bloomberg Radio numerous times .His articles have been published in Barron's, Forbes, TheStreet.com and numerous other publications.
He can be reached at firstname.lastname@example.org or by calling (855)611-BEST.
Editor for The Biotech Forum & The Insiders Forum; two of the most subscribed to services available via SeekingAlpha's MarketPlace. Long time Real Money Pro contributor. Biotech investor for a quarter century and frequent speaker on the topic at investment conferences like the MoneyShow and in interviews. For FREE weekly investment reports on small, attractive biotech stocks just register at biotechfreereports.com. To get my articles and instablogs as soon as they are published, please hit my profile and become a real-time follower.
Peter Geschek is a freelance writer, investor and the publisher of www.medfrontiers.com website. This is a site for medical innovation news and clinical trials news. Short, concise, important information about the latest is biotech and pharmaceuticals.
I am business graduate with a professional certification in F&A. I have been associated with the academic field, teaching both short and long courses on Finance and Accounting but my passion is following and writing about good investments.
Team StockMatusow.com research and writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about 17 years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Additionally, Dan is a Scientist and inventor. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunoncology focused approaches. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team.
Places you can follow Scott are:
Places to follow Dan are:
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors